- A class action lawsuit has been filed against **Alto Neuroscience, Inc.** (NYSE: ANRO) for investors who purchased securities between **February 2, 2024 and October 22, 2024**.  **[1677077_e4cacd7628bd4299a74f85e7668f8b27_0]** 
- The lawsuit alleges that the company made false or misleading statements regarding its drug candidate, ALTO-100, which was less effective in treating Major Depressive Disorder (MDD) than represented, and that its prospects were overstated.  **[1677077_e4cacd7628bd4299a74f85e7668f8b27_0]** 
- On October 22, 2024, Alto Neuroscience announced that ALTO-100's Phase 2b trial did not meet its primary endpoint, causing the stock to fall nearly **70%**.  **[1677077_e4cacd7628bd4299a74f85e7668f8b27_0]** 
- Investors have until **September 19, 2025** to file a lead plaintiff motion.  **[1677077_e4cacd7628bd4299a74f85e7668f8b27_0]**

Alzamend Neuro (ALZN)